MarketPeel
Insider Trading Intelligence
AL

Adam D. Levy

ACRV
CHIEF FINANCIAL OFFICER · ACRIVON THERAPEUTICS, INC. · CIK 0002061876
FILING MIX · LIFETIME80%/20%
BUYS
4
SELLS
1
TOTAL VALUE
$16.5K
COMPANIES
1
ACTIVE SINCE
Apr 2025
HOLDINGS NOW
67,150
AVG SELL PX
$1.26
TRADE KIND
SHOWING 5 / 5
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 3 pending
Forward-return performance of every backtestable P/S trade by Adam D. Levy, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%+14.21%-0.72%+14.93%+14.93%
14d1+100.00%+3.28%+0.73%+2.55%+2.55%
30d1+0.00%-10.93%-1.25%-9.68%-9.68%
60d1+0.00%-7.10%-3.09%-4.01%-4.01%
90d1+0.00%-10.38%+0.59%-10.98%-10.98%
180d1(1 pending)
1y1(1 pending)
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ACRV · 67,150 shares · as of May 18, 2026
033,23166,46399,694132,9252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2025
2025
2025
2026
2026
FLOW · 4 buys / 1 sellsCOVERAGE · 5 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
46,16767,150May 18, 2026May 20, 2026View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
132,925132,925Mar 1, 2026Mar 3, 2026View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
8,832$1.70$15.0K20,983Jan 14, 2026Jan 16, 2026View →
ACRV
ACRIVON THERAPEUTICS, INC.
SALE
Chief Financial Officer
1,164$1.26$1.5K12,151Aug 1, 2025Aug 5, 2025View →
ACRV
ACRIVON THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
35,20935,209Apr 1, 2025Apr 3, 2025View →
Other insiders · ACRV
Loading peer insiders…
About this filer
CIK 0002061876
ROLE
Chief Financial Officer
PRIMARY
ACRV
COMPANIES
1
ACTIVE SINCE
Apr 2025
MARKETPEEL · /INSIDER/0002061876DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback